1. Home
  2. REGCP vs IMNM Comparison

REGCP vs IMNM Comparison

Compare REGCP & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regency Centers Corporation

REGCP

Regency Centers Corporation

N/A

Current Price

$23.45

Market Cap

0.0

Sector

N/A

ML Signal

N/A

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.00

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
REGCP
IMNM
Founded
N/A
2006
Country
United States
United States
Employees
507
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
2.6B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
REGCP
IMNM
Price
$23.45
$22.00
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$32.80
AVG Volume (30 Days)
5.5K
900.7K
Earning Date
N/A
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
51.40
EPS
N/A
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1,127.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$22.35
$7.96
52 Week High
$24.74
$27.65

Technical Indicators

Market Signals
Indicator
REGCP
IMNM
Relative Strength Index (RSI) 55.37 49.13
Support Level $23.27 $19.28
Resistance Level $23.51 $23.25
Average True Range (ATR) 0.11 1.22
MACD 0.00 0.05
Stochastic Oscillator 68.97 56.39

Price Performance

Historical Comparison
REGCP
IMNM

About REGCP Regency Centers Corporation

Regency Centers is one of the largest shopping center-focused retail REITs. The company's portfolio includes an interest in 481 properties, which includes over 58 million square feet of retail space following the completion of the Urstadt Biddle acquisition in August 2023. The portfolio is geographically diversified with 22 regional offices and no single market representing more than 12% of total company net operating income. Regency's retail portfolio is primarily composed of grocery-anchored centers, with 80% of properties featuring a grocery anchor and grocery stores representing 20% of annual base rent.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: